EGFR and lung carcinoma: Although EGFR mutations have been reported to predict sensitivity to EGFR tyrosine kinase inhibitors in lung cancer [25], little is known about the impact of EGFR amplifications in either for selecting patient to anti-EGFR treatment or as a role in resistance.